Your browser doesn't support javascript.
loading
The Chimeric Binjari-Zika Vaccine Provides Long-Term Protection against ZIKA Virus Challenge.
Hazlewood, Jessamine E; Tang, Bing; Yan, Kexin; Rawle, Daniel J; Harrison, Jessica J; Hall, Roy A; Hobson-Peters, Jody; Suhrbier, Andreas.
Afiliação
  • Hazlewood JE; Inflammation Biology Group, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4029, Australia.
  • Tang B; Inflammation Biology Group, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4029, Australia.
  • Yan K; Inflammation Biology Group, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4029, Australia.
  • Rawle DJ; Inflammation Biology Group, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4029, Australia.
  • Harrison JJ; School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, QLD 4072, Australia.
  • Hall RA; School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, QLD 4072, Australia.
  • Hobson-Peters J; Australian Infectious Disease Research Centre, GVN Center of Excellence, The University of Queensland and QIMR Berghofer Medical Research Institute, St Lucia, QLD 4067, Australia.
  • Suhrbier A; School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, QLD 4072, Australia.
Vaccines (Basel) ; 10(1)2022 Jan 06.
Article em En | MEDLINE | ID: mdl-35062746
We recently developed a chimeric flavivirus vaccine technology based on the novel insect-specific Binjari virus (BinJV) and used this to generate a chimeric ZIKV vaccine (BinJ/ZIKA-prME) that protected IFNAR-/- dams and fetuses from infection. Herein, we show that a single vaccination of IFNAR-/- mice with unadjuvanted BinJ/ZIKA-prME generated neutralizing antibody responses that were retained for 14 months. At 15 months post vaccination, mice were also completely protected against detectable viremia and substantial body weight loss after challenge with ZIKVPRVABC59. BinJ/ZIKA-prME vaccination thus provided long-term protective immunity without the need for adjuvant or replication of the vaccine in the vaccine recipient, both attractive features for a ZIKV vaccine.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Vaccines (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Austrália País de publicação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Vaccines (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Austrália País de publicação: Suíça